SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

The community is intensely focused on the long-anticipated SpaceX IPO, with active debates centered on whether the company represents a revolutionary aerospace investment or a speculative bubble destined to become a massive pump-and-dump scheme. Investors are also aggressively scouting for proxy plays and space-sector ETFs to gain exposure, while expressing widespread skepticism toward various crypto-based tokens claiming to represent the company.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is gaining significant attention following the news that Quantinuum has filed for an IPO, which is fueling excitement around the project's long-term utility in the quantum computing and blockchain infrastructure space. The community is actively discussing the token's scarcity, institutional partnerships in finance, and the potential for a supply shock as these enterprise-grade use cases continue to develop.

Radium is a Proof-of-Stake cryptocurrency that serves as the base blockchain for SmartChain Core which expands the utility of Radium far beyond that of a standard coin, with features such as identity-address linkage, proof-of-existence, file checksum verification and validation, and decentralized elections and voting. All of these features exist in a 100% distributed data-layer within the Radium blockchain.

Validity

The acquisition of Valaris by Transocean is driving significant market attention as investors weigh the potential for a combined pricing powerhouse in the offshore drilling sector. Community members are actively debating the long-term strategic benefits of this merger, including debt reduction and improved contract backlogs, while closely monitoring market rumors regarding potential interest from major institutional energy investors.

Baron ETF Trust - Baron First Principles ETF

The Baron First Principles ETF is actively trending as retail investors seek accessible, direct exposure to SpaceX ahead of a potential IPO. Community discussion is heavily focused on the fund's unique holding of common shares compared to other private equity vehicles, though some investors are debating potential dilution risks as the ETF's assets grow.

Unleash Jugs

JUGS is gaining momentum as a newly launched meme-themed cryptocurrency, with community members highlighting its potential for rapid price volatility due to high token concentration among top holders. Investors are actively discussing the coin's early-stage growth and speculative appeal, frequently referencing its concentrated supply as a catalyst for potential short-term spikes.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is currently trending due to its unique position as a decentralized, Bitcoin-native memecoin that maintains a dedicated following despite significant market volatility. Community members are actively debating its structural fundamentals and long-term viability as a store of value, while frequently contrasting its fair-launch model against centralized exchange practices and manipulated assets.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is gaining momentum as investors pivot toward domestic critical mineral supply chains, with community members highlighting its potential as a specialized metals-tech integration play. While the stock has seen significant volatility, sentiment is currently driven by discussions around its low float, recent strategic partnerships, and its potential to reduce reliance on international metal markets.

Investment Managers Series Trust II - Tradr 2X Long AAOI Daily ETF

The Tradr 2X Long AAOI Daily ETF

AAOX is generating intense community interest as a leveraged vehicle for tracking the volatile price swings of Applied Optoelectronics within the optical networking and AI infrastructure sector. Traders are actively debating entry and exit points, focusing on the ETF's aggressive daily multipliers while cautioning one another about the inherent risks of holding leveraged positions during periods of high market fluctuation.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending following a first-quarter earnings report that beat expectations, prompting the company to raise its full-year guidance and sparking investor optimism about its turnaround strategy. The community is actively debating whether this momentum signals a sustainable recovery for the department store or if it remains a value trap, with much of the discussion focused on the stock's significant real estate holdings and the potential for future M&A activity.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

PDD is seeing significant volatility as investors weigh intense competitive pressures and mixed quarterly growth against heavy institutional call flow and speculative upside bets. The community remains divided, with some highlighting the stock's long-term valuation appeal and dominant market position, while others remain cautious due to regulatory scrutiny, earnings fluctuations, and the broader impact of cross-border trade policies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that results from the Phase 3 Orbit and Cosmic studies for an experimental drug designed to help people with brittle bone disease did not significantly reduce annualized clinical fracture rates.</li><li>Both studies showed improvements in bone mineral density, the company said.&nbsp;</li><li>Ultragenyx also noted that it will reduce expenses significantly after evaluating its planned operations.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) shares plunged over 41% on Monday after the company announced disappointing results from its Phase 3 studies for its experimental drug designed to help people with brittle bone disease.The company said that results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), conducted in partnership with Mereo Biopharma (MREO), did not significantly reduce annualized clinical fracture rates compared to placebo or bisphosphonates, respectively. However, both studies showed improvements in bone mineral density, the company said.The firm also said it will significantly reduce expenses after evaluating its planned operations.<h2 class="st-heading-2">Trial Details</h2>In the Orbit study, participants showed substantial improvements in bone mineral density compared with the placebo group. However, that did not result in a significant reduction in annualized fracture rates, since the placebo group also had a low fracture rate, the company noted.In the Cosmic study, which included pediatric patients, the baseline fracture rate was substantially higher than in the Orbit patient group. While the study showed improvements in bone mineral density and a reduction in annualized fracture rate compared to bisphosphonate-treated patients, the results were not statistically significant.“We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant pain, disability, and disease burden,” said Emil Kakkis, chief executive officer and president of Ultragenyx. “We continue to explore the data to gain deeper understanding of the findings.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RARE">RARE shares</a> jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. The stock was also among the top trending tickets on the platform.<figure class="image"><img style="aspect-ratio:1283/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_9_02_19_PM_png_233d427277.webp" alt="On Stocktwits, retail sentiment around RARE shares jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. " width="1283" height="153"></figure>Shares of RARE are down over 51% in the past year.Editor's Note: The story has been updated to reflect that the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta was conducted in partnership with Mereo Biopharma.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did RARE Stock Plunge Over 41% Today?

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 

Equity

Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Merck (MRK) and Verona Pharma Plc. (VRNA) on Wednesday announced that the two companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma.Merck will <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec/">acquire</a> Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.The purchase price represents a 23.2% upside to Verona ADS’s closing price on Tuesday.VRNA shares were trading 21% higher in the pre-market session at the time of writing.London-based Verona is a biopharmaceutical company focused on respiratory diseases.Through the acquisition, <a href="https://stocktwits.com/symbol/MRK">Merck</a> will add Ohtuvayre to its expanding cardiovascular and pulmonary pipeline and portfolio. Ohtuvayre was approved by the U.S. Food and Drug Administration in 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The drug is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis.Ohtuvayre brought in net sales of $71.3 million for Verona in the first quarter of 2025, marking a growth of 95% from the fourth quarter of 2024.The acquisition, Merck said, is expected to drive growth into the next decade.“Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders,” Merck CEO Robert M Davis said.The transaction, which was unanimously approved by both the Merck and <a href="https://stocktwits.com/symbol/VRNA">Verona Pharma</a> Boards of Directors, is expected to close in the fourth quarter of 2025.On Stocktwits, retail sentiment around Verona jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’ levels.Retail sentiment around Merck, meanwhile, continues to be in the ‘bearish’ territory, accompanied by ‘normal’ message volume.Shares of VRNA have risen 87% this year while MRK shares have declined nearly 18%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dollar-climbs-off-multi-year-lows-as-report-unpacks-bessent-influence-on-tariff-timeline/chFUtg2R5i2">Dollar Climbs Off Multi-Year Lows As Report Unpacks Bessent’s Influence On Trump Tariff Timeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline

Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

JDOC
JPMorgan Healthcare Leaders ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest JDOC News

JDOCJPMorgan Healthcare Leaders ETF